[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT02575365 : Effect of Fingolimod on Neurodegeneration|
|Ages||Min: 18 Years Max: 65 Years|
- 1. Diagnosed with RRMS as described in 2010 McDonald criteria (36) 2. Provided
written informed consent prior to any intervention 3. Unresponsive to treatment with
a beta interferon or glatiramer acetate for a minimum of one year at and at adequate
dose and with high disease activity (Unresponsive patients: patients with no changes
in relapses, increased relapses, severer relapses with one-year treatment or those
who had had at least one relapse during the past one year under previous treatments
and one or multiple contrast enhancing lesions in cranial MRI or increased T2 lesions
in successive MRIs) 4. EDSS score below 5.5 at screening
- 1. Patients with primary or secondary progressive or progressive relapsing MS. 2.
Patients with known contraindications for fingolimod treatment. 3. Other coexistent
autoimmune diseases including Hashimoto thyroiditis, systemic lupus erythematosus,
rheumatoid anthiritis, psoriasis etc.
4. Patients with any of the following cardiovascular conditions:
- Resting heart rate < 45 bpm/min
- Cardiac failure at any time during the first study visit (Class III as per NYHA
classification) or significant heart disease as judged by the physician
- Myocardial infarction during the last 6 months
- History of Mobitz Type II grade 2 AV block
- Past or current grade 3 AV block
- Confirmed history of sick sinus syndrome or sino-atrial heart block
- arrhythmia requiring current treatment with Class Ia drugs (ajmaline,
disopyramid, procainamide, quinidine)
- hypertension uncontrolled with medication 5. History of malignancy of any organ
system (other than localized basal cell carcinoma of the skin), treated or
untreated, within the past 5 years, regardless of whether there is evidence of
local recurrence or metastases.
6. Pregnant or nursing (lactating) women, where pregnancy is defined as the
state of a female after conception and until the termination of gestation,
detected by urinalysis and confirmed by a positive hCG laboratory test.
7. Negative for varicella-zoster virus IgG antibodies at screening. Patients who
have negative results for varicella-zoster virus IgG antibodies can be included
in the study after vaccination for varicella-zoster virus.
8. Active systemic bacterial, viral or fungal infections, or diagnosis of AIDS,
Hepatitis B, Hepatitis C infection defined as a positive HIV antibody, Hepatitis
B surface antigen or Hepatitis C antibody tests, respectively 9. History of
previous fingolimod therapy 10. Patient who received any of the treatments
1. Corticosteroids or adrenocorticotropic hormone (ACTH) during the last 1
2. Immunosuppressive medications such as azathioprine or methotrexate etc.
3. Immunoglobulin treatment during the last 3 months
4. Cladribine, cyclophosphamide, mitoxantrone, natalizumab at any time
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02575365
| Link to official Clinicaltrials.gov listing